Drug prices are still rising, with manufacturers hiking up prices at the start of 2020. And the “reluctance” from the Republican party to challenge those rising prices could become a huge liability for the upcoming 2020 election, according to The Hill.

Drug prices are still rising in 2020, but the rate of inflation appears to be slowing down. For investors, however, that might be good news, according to The Wall Street Journal.

Hospital charges are on their way up, driving up private payments that are already significantly higher than public payments, according to a new study published in Health Affairs. However, the widening gap between private and public payments appears to be slowing down.

A handful of major drugstore retailers are suing Ohio doctors over their role in the national opioid abuse and overdose epidemic, claiming pharmacies alone shouldn't be found liable in litigation.

The White House has proposed a new set of principles for governing the development of AI solutions throughout the United States.

Healthcare administrative and bureaucracy costs in the U.S. reached $812 billion in 2017––a whopping four times higher than Canada, according to a new study by Harvard researchers. And Medicare for all could be the way to achieve huge savings.

The Trump administration is pursuing a plan to allow the importation of certain drugs from Canada and other countries in an effort to lower drug prices. But the plan isn’t likely to work, according to a Forbes op-ed.

A membership-based primary care services company backed by private equity groups, One Medical Group, has filed for an initial public offering with the SEC.